A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults

NCT04908722 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1609

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Prevention

Interventions

BIOLOGICAL: Ad26.COV2.S

Sponsor

Janssen Vaccines & Prevention B.V.